Evidence map›Paper›PMID 29449673›Full record

ArticleBritish journal of cancer2018

The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients.

Enrica Rampazzo, Paola Del Bianco, Roberta Bertorelle, Caterina Boso, Alessandro Perin, Giovanna Spiro, Francesca Bergamo, Claudio Belluco, Angela Buonadonna, Elisa Palazzari and 4 more

Erratum issued Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in British journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03962088 (Timing To Minimally Invasive Surgery After Neoadjuvant Chemoradiotherapy For Rectal Cancer), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03962088 unknown statusnot on this mapstarted 2019, after this paper: background citation

Timing To Minimally Invasive Surgery After Neoadjuvant Chemoradiotherapy For Rectal Cancer: A Multicenter Randomized Controlled Trial - Biomarkers SubStudy

TypeobservationalSponsorAzienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di AlessandriaRan2019 to 2025Enrolled200ConditionsRectal CancerArmsmiRNA
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 25 citations in OpenAlex.

  1. Potential of hTERT mRNA for the management of advanced head and neck squamous cell carcinoma.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Biological Predictors ofFrontiers in oncology · 2021
    Article
  15. Article
  16. Detection ofOncotarget · 2020
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Enrica RampazzoSection of Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Via Gattamelata 64, Padova 35128, Italy.
Paola Del BiancoClinical Trials and Biostatistic Unit, Istituto Oncologico Veneto (IOV)-IRCCS, Via Gattamelata 64, Padova 35128, Italy.
Roberta BertorelleImmunology and Molecular Oncology Unit, IOV- IRCCS, Via Gattamelata 64, Padova 35128, Italy.
Caterina BosoRadiotherapy and Nuclear Medicine Unit, IOV-IRCCS, Via Gattamelata 64, 35128 Padova, Italy.
Alessandro PerinSection of Surgery, Department of Surgery, Oncology and Gastroenterology, Via Giustiniani 1, University of Padova, Padova 35128, Italy.
Giovanna SpiroSection of Surgery, Department of Surgery, Oncology and Gastroenterology, Via Giustiniani 1, University of Padova, Padova 35128, Italy.
Francesca BergamoMedical Oncology Unit 1, IOV-IRCCS, Via Gattamelata 64, Padova 35128, Italy.
Claudio BellucoDepartment of Surgical Oncology, Centro di Riferimento Oncologico (CRO)-IRCCS, Aviano, Italy.
Angela BuonadonnaDepartment of Medical Oncology B, CRO-IRCCS, Aviano, Italy.
Elisa PalazzariRadiation Oncology, CRO-IRCCS, Aviano, Italy.
Sara LonardiMedical Oncology Unit 1, IOV-IRCCS, Via Gattamelata 64, Padova 35128, Italy.
Antonino De PaoliRadiation Oncology, CRO-IRCCS, Aviano, Italy.
Salvatore PucciarelliSection of Surgery, Department of Surgery, Oncology and Gastroenterology, Via Giustiniani 1, University of Padova, Padova 35128, Italy.
Anita De RossiSection of Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Via Gattamelata 64, Padova 35128, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Padua · ITCentro di Riferimento Oncologico · ITIstituto Oncologico Veneto · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPreoperative chemoradiotherapy (CRT) followed by surgery is the standard care for locally advanced rectal cancer, but tumour response to CRT and disease outcome are variable. The current study aimed to investigate the effectiveness of plasma telomerase reverse transcriptase (TERT) levels in predicting tumour response and clinical outcome.

methods176 rectal cancer patients were included. Plasma samples were collected at baseline (before CRT=T0), 2 weeks after CRT was initiated (T1), post-CRT and before surgery (T2), and 4-8 months after surgery (T3) time points. Plasma TERT mRNA levels and total cell-free RNA were determined using real-time PCR.

resultsPlasma levels of TERT were significantly lower at T2 (P<0.0001) in responders than in non-responders. Post-CRT TERT levels and the differences between pre- and post-CRT TERT levels independently predicted tumour response, and the prediction model had an area under curve of 0.80 (95% confidence interval (CI) 0.73-0.87). Multiple analysis demonstrated that patients with detectable TERT levels at T2 and T3 time points had a risk of disease progression 2.13 (95% CI 1.10-4.11)-fold and 4.55 (95% CI 1.48-13.95)-fold higher, respectively, than those with undetectable plasma TERT levels.

conclusionsPlasma TERT levels are independent markers of tumour response and are prognostic of disease progression in rectal cancer patients who undergo neoadjuvant therapy.

Indexed as

AgedBiomarkers, TumorChemoradiotherapy, AdjuvantFemaleHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPredictive Value of TestsPrognosisProgression-Free SurvivalRectal NeoplasmsRetrospective StudiesRNA, NeoplasmTelomeraseBiomarkers, TumorRNA, NeoplasmTelomeraseTERT protein, human

Identifiers

PMID29449673
PMCPMC5877438
OpenAlexW2788796897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.